Optimal antithrombotic strategy in patients with atrial fibrillation beyond 1 year after drug-eluting stent...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) require anticoagulation and antiplatelet therapy.
• Guidelines suggest discontinuing antiplatelet therapy 1 year post-DES due to bleeding risk, but evidence is limited.

Purpose of the Study:

• To evaluate the non-inferiority of non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy compared to NOAC plus clopidogrel combination therapy.
• To determine the optimal antithrombotic strategy for AF patients beyond 12 months after DES implantation, focusing on net adverse clinical events (NACE).

Main Methods:

• The ADAPT AF-DES trial is a prospective, randomized, non-inferiority study involving 960 AF patients with a CHA2DS2-VASc score > 1, at least 12 months post-PCI with DES.
• Participants are randomized to receive either NOAC monotherapy or NOAC plus clopidogrel.
• The primary endpoint is NACE at 1 year, encompassing death, MI, stent thrombosis, stroke, embolism, and major/clinically relevant non-major bleeding.

Main Results:

• NACE rates will be compared between the NOAC monotherapy and combination therapy groups.
• The study aims to demonstrate that NOAC monotherapy is non-inferior to dual therapy in preventing NACE.
• Bleeding events and thrombotic events will be assessed as key components of NACE.

Conclusions:

• The ADAPT AF-DES trial will provide crucial evidence on the efficacy and safety of NOAC monotherapy versus dual therapy in AF patients post-DES.
• Findings will inform clinical practice regarding long-term antithrombotic management in this high-risk population.
• The study seeks to establish a safer and potentially more effective antithrombotic regimen.